A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant ''CMV at risk'' recipients

By Yang H.C.   Holman M.J.   Langhoff E.   Dellock C.A.   Gupta M.   Ulsh P.J.   Ahsan N.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 1125-1126

Elsevier

Access to resources Recommend Favorite

Incidence of cmv infection and cmv disease in allogeneic transplanted patients - From no prophylaxis to preemptive treatment

By Meuleman N.   Debruyne J.M.   Jacquy C.   Bron D.  

Experimental Hematology, Vol. 28, Iss. 12, 2000-12 ,pp. : 1501-1501

Elsevier

Access to resources Recommend Favorite

Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy

By Morales E.   Andres A.   Gonzalez E.   Herrero J.C.   Munoz M.A.   Ortiz M.   Espejo B.   Lumbreras C.   Morales J.M.   Aguado J.M.  

Transplantation Proceedings, Vol. 34, Iss. 1, 2002-02 ,pp. : 73-74

Elsevier

Access to resources Recommend Favorite

Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir

By Paniagua M.J.   Crespo-Leiro M.G.   De la Fuente L.   Tabuyo T.   Mosquera I.   Canizares A.   Naya C.   Farina P.   Juffe A.   Castro-Beiras A.  

Transplantation Proceedings, Vol. 34, Iss. 1, 2002-02 ,pp. : 69-70

Elsevier

Access to resources Recommend Favorite

Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation

By Tomonari Akira  

Annals of Hematology, Vol. 83, Iss. 9, 2004-09 ,pp. : 573-577

Springer Publishing Company

Access to resources Recommend Favorite